Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK, discusses the final overall survival (OS) results from the Phase III KEYNOTE-522 trial (NCT03036488) of pembrolizumab plus chemotherapy in patients with early-stage triple-negative breast cancer (TNBC). The addition of pembrolizumab to neoadjuvant and adjuvant therapy significantly improved OS and event-free survival (EFS) compared to chemotherapy alone. Safety profiles were consistent, with increased immune-mediated adverse events in the pembrolizumab group. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
